PBM Reporting Transparency Act
- Bill Number
- S. 3729
- Origin Chamber
- Senate
- Congress
- 119th Congress, Session 2
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2026-01-29: Read twice and referred to the Committee on Finance.
- Last Updated
- 2026-02-20T18:20:13Z
AI-Generated Summary
Purpose
The PBM Reporting Transparency Act (S. 3729) aims to increase transparency in how pharmacy benefit managers (PBMs)—companies that negotiate drug prices and manage prescription benefits for health plans—interact with Medicare drug coverage options. It requires the Medicare Payment Advisory Commission (MedPAC), an independent agency that advises Congress on Medicare issues, to analyze and report on these agreements to help inform potential improvements in drug pricing and beneficiary costs.
Key Provisions
- Short Title: The legislation is titled the "PBM Reporting Transparency Act."
- Reporting Requirements for MedPAC:
- Initial Report: Due by the first March 15 that occurs at least 2 years after the Secretary of Health and Human Services makes relevant data available to MedPAC. This report must cover agreements between PBMs and two types of Medicare drug plans:
- Prescription Drug Plans (stand-alone Medicare Part D plans for drug coverage).
- MA-PD Plans (Medicare Advantage Prescription Drug plans, which combine medical and drug coverage under Medicare Part C).
- Content includes:
- Descriptions of trends and patterns in these agreements, such as averages, totals, and other key figures.
- Analysis of how differences in agreements affect enrollee out-of-pocket costs (what beneficiaries pay directly), average pharmacy reimbursements (payments to pharmacies), and other related impacts.
- Any recommendations MedPAC deems appropriate.
- Final Report: Due 2 years after the initial report. This must describe changes in the analyzed information over time and include any appropriate recommendations.
Significant Changes to Existing Law
- This bill introduces a new mandatory reporting obligation for MedPAC specifically focused on PBM agreements in Medicare Part D and Medicare Advantage drug plans.
- It does not amend or repeal existing laws but builds on current data-sharing mechanisms (assuming the Secretary provides the necessary data as referenced). No direct changes to PBM regulations, drug pricing rules, or Medicare operations are specified; the focus is solely on generating advisory reports.
Potential Impacts
- On Government Agencies: MedPAC will need to dedicate resources to data analysis and reporting, potentially influencing future Medicare policy decisions by Congress or the Department of Health and Human Services. This could lead to broader oversight of PBM practices without immediate regulatory shifts.
- On Citizens: Medicare beneficiaries enrolled in prescription drug or MA-PD plans may indirectly benefit from greater transparency, which could highlight ways to reduce out-of-pocket drug costs or improve pharmacy payments. However, impacts depend on whether Congress acts on the reports.
- On International Relations: No apparent impacts, as the bill is limited to domestic Medicare administration.
Main Stakeholders Affected
- MedPAC: Directly tasked with preparing and submitting the reports.
- Congress (especially the Senate Committee on Finance): Receives the reports to guide potential legislation on drug pricing and Medicare reforms.
- Pharmacy Benefit Managers (PBMs): Their agreements with Medicare plans will be scrutinized, potentially exposing practices to public and legislative review.
- Medicare Plans and Providers: Prescription Drug Plans, MA-PD Plans, and pharmacies may face indirect effects if reports lead to policy changes affecting reimbursements or negotiations.
- Medicare Enrollees: Older adults and disabled individuals relying on Medicare drug coverage, who could see changes in costs or access based on future actions informed by the reports.
Notable Legal, Constitutional, or Political Implications
- Legal Implications: The bill enhances accountability in Medicare's private-sector partnerships (e.g., with PBMs) by leveraging existing data access, without creating new enforcement powers. It could set a precedent for similar transparency requirements in other federal health programs.
- Constitutional Implications: None significant; it aligns with Congress's authority under the Constitution to oversee federal spending and programs like Medicare.
- Political Implications: Bipartisan sponsorship (from Senators Warner, Tillis, Cortez Masto, and Marshall) suggests broad interest in addressing drug pricing concerns. The reports could fuel debates on PBM reform, potentially leading to stricter regulations on intermediaries in the pharmaceutical supply chain, though the bill itself is non-controversial as it only mandates analysis rather than direct intervention.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Cosponsors (3)
Sen. Tillis, Thomas [R-NC], Sen. Cortez Masto, Catherine [D-NV], Sen. Marshall, Roger [R-KS]
Recent Actions
- 2026-01-29: Read twice and referred to the Committee on Finance.
- 2026-01-29: Introduced in Senate
Bill Versions
- PBM Reporting Transparency Act — issued 2026-01-29 — PDF (3 pages)